Super selective intra-arterial cerebral infusion (SSIACI) for newly diagnosed and recurrent glioblastoma Authors Syed Sarmad Bukhari Northwest School of Medicine, Peshawer, Pakistan; Noman Ahmed Aga Khan University Hospital, Karachi, Pakistan Muhammad Shahzad Shamim Aga Khan University Hospital, Karachi, Pakistan DOI: https://doi.org/10.47391/JPMA.24-55 Abstract Chemotherapy with various modalities is the standard of care in the management of newly diagnosed and recurrent glioblastoma. Current guidelines recommend intravenous administration of systemic chemotherapy. However, the blood brain barrier (BBB) restricts ionized molecules larger than 180 Da (Daltons) while most chemotherapeutic agents are between 200-1200 Da (TMZ [194 Da]). The doses administered are restricted by their systemic toxicity. Super selective intra-arterial cerebral infusion (SSIACI) can administer a localized regular or higher dose of chemotherapy that circumvents the systemic circulation. This is accompanied by disruption of the BBB (BBBd) which can be achieved in a number of ways (IV mannitol, MRIgFUS and bradykinins etc). With super selective catheterization, the drug’s volume of distribution (Vd) is restricted to a targetted area. Additionally, following drug delivery, flow may be arrested to prevent drug washout with blood flow.1 Continued... Downloads Full Text Article Published 2024-06-28 How to Cite Syed Sarmad Bukhari, Noman Ahmed, & Muhammad Shahzad Shamim. (2024). Super selective intra-arterial cerebral infusion (SSIACI) for newly diagnosed and recurrent glioblastoma. Journal of the Pakistan Medical Association, 74(7), 1380–1381. https://doi.org/10.47391/JPMA.24-55 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 74 No. 7 (2024): JULY Section EVIDENCE BASED NEURO-ONCOLOGY License Copyright (c) 2024 Journal of the Pakistan Medical Association This work is licensed under a Creative Commons Attribution 4.0 International License.